ReviewApplied microbiology and biotechnology2021
Biotech in China 2021, at the beginning of the 14th five-year period ("145").
Review in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Multi-Modal Topology-Aware Graph Neural Network for Robust Chemical-Protein Interaction Prediction.International journal of molecular sciences · 2025Article
- TCoCPIn reveals topological characteristics of chemical protein interaction networks for novel feature discovery.Scientific reports · 2025Article
- China's position and competitiveness in the global antibiotic value chain: implications for global health.Globalization and health · 2024Article
- The roadmap of bioeconomy in China.Engineering biology · 2022Review
- Article
- Current situation and future development of the biopharmaceutical industry in China: A mixed-method study.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As China assumes a more and more dominant role in global science, this mini-review attempts to provide a bird's eye view on how the bio-digital revolution impacts China's biosciences and bioindustry. Triggered by top-down political programs and the buildup of an impressive infrastructure in science, information technology, and education, China's biomedical and MedTech industries prosper. Plant and animal breeding programs transform agriculture and food supply as much as the Internet of things, and synthetic biology offers new opportunities for the manufacturing of specialty chemicals within the Chinese version of a "bioeconomy." It is already becoming apparent that the new five-year period "145" (2021-2025) will further emphasize emission control, bioenvironmental protection, and more supply of biomass-derived energy. This review identifies key drivers in China's government, industry, and academia behind these developments and details many access points for deeper studies. KEY POINTS: Biotechnology in China Biomedical technology New five-year period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.